New chemotherapy options for triple-negative breast cancer (review of literature)

New chemotherapy options for triple-negative breast cancer (review of literature)

In this article the authors on the basis of the analysis of the medical literature describe the purpose, chemotherapy options and future de-velopment in chemotherapy in patients with triple-negative breast cancer.

Bibliographic Details
Main Authors:	M A Sekundova, A M Zdvizhkov, V I Borisov
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2014-03-01
Series:	Современная онкология
Subjects:	triple-negative breast cancer chemotherapy
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26923

Similar Items

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
by: Olga O Gordeeva, et al.
Published: (2019-09-01)

Orbital Metastasis from Triple-Negative Breast Cancer: Case Report and Literature Review
by: Kamal El Bakraoui, et al.
Published: (2020-09-01)

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
by: Jessa Gilda P. Pandy, et al.
Published: (2019-11-01)

NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
by: Paul B. Mullan, et al.
Published: (2019-04-01)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
by: Olga Caramelo, et al.
Published: (2019-03-01)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
by: Xingfa Huo, et al.
Published: (2021-01-01)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
by: Yoshimasa Kosaka, et al.
Published: (2020-02-01)

Immunotherapeutic interventions of Triple Negative Breast Cancer
by: Zehuan Li, et al.
Published: (2018-05-01)

Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
by: KONG Tiandong, et al.
Published: (2021-05-01)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01)

Comparison of outcomes between metaplastic and triple-negative breast cancer patients
by: Praveen Polamraju, et al.
Published: (2020-02-01)

Moringa Oleifera Seed Extract Concomitantly Supplemented with Chemotherapy Worsens Tumor Progression in Mice with Triple Negative Breast Cancer and Obesity
by: Elizabeth R. M. Zunica, et al.
Published: (2021-08-01)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
by: Chen-Lu Lian, et al.
Published: (2021-10-01)

Current and emerging treatment options in triple-negative breast cancer
by: Omer Dizdar, et al.
Published: (2011-12-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy
by: Bray Denard, et al.
Published: (2018-08-01)

Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers
by: Yufei Lv, et al.
Published: (2021-03-01)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
by: Javier Pérez-Pena, et al.
Published: (2019-12-01)

Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement
by: Ibnu Purwanto, et al.
Published: (2020-02-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
by: Qian Wang, et al.
Published: (2018-08-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
by: Lin-Yu Xia, et al.
Published: (2020-06-01)

Bioactive nanotherapeutic trends to combat triple negative breast cancer
by: Pallabita Chowdhury, et al.
Published: (2021-10-01)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
by: A. I. Chertkova, et al.
Published: (2018-11-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
by: Omarini C, et al.
Published: (2018-01-01)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
by: Yanding Zhao, et al.
Published: (2020-09-01)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
by: Liu MC, et al.
Published: (2019-12-01)

Prognostic significance of adipophilin expression in biopsy specimens of patients with triple‑negative breast cancer
by: Ishida, M., et al.
Published: (2022)

MicroRNAs and Triple Negative Breast Cancer
by: Marilena V. Iorio, et al.
Published: (2013-11-01)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
by: Gizem Oner, et al.
Published: (2021-09-01)

Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy
by: Olivia IONESCU, et al.
Published: (2016-06-01)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
by: Shanshan Sun, et al.
Published: (2021-03-01)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
by: Inna P. Ganshina, et al.
Published: (2021-02-01)